This application describes embodiments of apparatuses, methods, materials, methods of manufacture, and systems for the treatment of wounds, specifically to aid in packing and treating wounds.
This application further relates to improved wound dressing materials. In particular this application relates to wound dressing materials with improved drapeability, which allows them to more easily conform to the shape of a surface over which they are placed. Especially, but not exclusively, the present application relates to foam materials, especially those suitable for use in negative pressure wound therapy (NPWT).
Wound dressings are commonly manufactured from sheet materials. These materials include transparent films and adhesives and opaque foams and fibres. These materials generally retain their transparency or opacity upon fluid absorption, the exception being carboxymethylcellulose-based hydrofibre (which is initially opaque and becomes transparent when wet). Wound dressings which rely upon a foam element for exudate management are opaque and require removal and exchange for a new dressing during every wound inspection. This is a disadvantage of opaque dressings, for example, including a foam element. Foam-based dressings also have limited extensibility due to the mechanical properties inherent in a material of foam structure; this can cause problems when attempting to dress locations of high curvature. In spite of these performance disadvantages, the use of foam-based wound dressings or dressing elements dominates woundcare. This may be due to their excellent absorbency, low dry weight, cut-ability and mouldability. Limited extensibility is not restricted to foams; this is also a property of the films commonly applied in medical devices.
The single-axis lattice cutting of monolithic materials, including the sheet materials utilised in wound dressings has been disclosed in (GB821,959). However, once cut, these materials are not extended in any manner until post-application to the wound, and only then as a result of the flexing of the limb or other part of the body on which the dressing is worn. Whilst this type of dressing does enable some ease of movement for the patient, the material only permits minimal visibility of the wound. Additionally, the size of apertures and thus the permeability of the material, particularly important for the release of exudates from the wound, cannot be controlled.
There is a need for a wound dressing which can be established in an extended conformation both prior to application and during application to a wound.
There is a need for a wound dressing which can be retained within a defined extended conformation both prior to application and during application to a wound.
There is a need for a wound dressing which allows visualisation of the wound immediately upon application of the dressing.
There is a need for a wound dressing which has a controlled aperture profile, which enables control of exudate egress.
There is a need for a wound dressing which has a controlled contractile profile for promoting wound closure.
NPWT is a relatively new treatment for open wounds. Typically in NPWT the wound cavity or surface is filled or covered with a material that allows the transmission of a partial vacuum (i.e. does not completely collapse) to the wound bed when a negative pressure is applied to the wound area, and also allows fluids to pass from the wound bed towards the source of negative pressure. There are two primary approaches to NPWT, gauze or foam types. The gauze type (also referred to as the Chariker-Jeter technique) involves the use of a drain wrapped in gauze topped by a sealed dressing. The foam type involves the use of foam placed over or in the wound. The present invention is directed primarily, but not exclusively, towards the foam type of NPWT.
In foam based NPWT the wound is filled or covered with a porous, compressible foam packing material and covered over and sealed with flexible sheet (a drape) that is fairly impermeable to fluids. A tube is inserted under or through the drape into the wound site and its distal end is connected to a vacuum source (commonly a pump). The wound cavity, enclosed by the drape and tissue, contracts under the force of atmospheric pressure and compresses the packing material visibly. Gross tissue movement ceases after a few tens of seconds and fluid flow from the wound (withdrawn from the tissue) ensues. The fluid is transmitted through the packing material and up the vacuum tube to a collection receptacle positioned between the distal end of the tube and the vacuum source. The material mechanically supports the tissue to which it is applied, and also allows the free flow of fluids away from the site when a vacuum is applied, even when compressed. A good material for this application is hydrophobic, reticulated polyurethane foam of very high free internal volume. However, articles of high free internal volume tend to be poorly drapeable due to the requirement for their structure to mechanically support their high free internal volume, and this is the case in current foams applied in NPWT.
The foams, which in other regards are near optimal for NPWT, are very poorly conformable to the site of application especially prior to the application of a covering drape and vacuum being applied. This is true for cavity wounds of concave geometry, and surface wounds, e.g. to the extremities, of convex geometry.
Monolithic articles of high free internal volume are able to support their own external dimensions by virtue of their mechanical properties, i.e. they are relatively stiff. This factor has the side effect of making such solid objects poorly drapeable and this is not desirable for all applications. For some applications, the mechanical integrity of the structure is not required at the scale of the monolith itself.
For medical applications involving the application of articles to the body, both good drapeability and good resistance to compression under loading are desirable attributes.
The visibility through an opaque material can be increased by the creation of apertures through it. However, the creation of apertures, for example by hole-punching, has the disadvantages of resulting in the generation of waste and also the mechanical weakening of the material. By forming through slits in a material, these slits being capable of expanding to form apertures on extension of the material, we have been able to achieve both increased visibility of the wound and increased extensibility of the material, without significant material waste. In this manner, it is also possible to achieve extension of the slit to form a circular hole without mechanically weakening the material.
Therefore, according to an aspect of the invention there is provided a lattice comprising a material having at least one slit, the slit being capable of expansion into an aperture, the lattice having
Material having a slit or plurality of slits is referred to as a lattice, and prior to extension of the material, the lattice is referred to as being in a “first conformation” or “initial conformation” or “closed lattice conformation” wherein the slits are substantially closed. A substantially closed slit is a slit which has a conformation that allows no or substantially no visual inspection of the wound through the lattice with the naked eye.
Preferably, the material is a polyurethane foam or a silicone elastomer, for example.
The cutting of a largely two-dimensional or flat material and a three-dimensional material to form slits can be achieved by any means known in the art, for example laser cutting or blade pressing. The cutting method can be a batch process or continuous process. The cutting arrangements of two-dimensional material are preferably two-dimensional and along the x and y plane. The cutting arrangements of three-dimensional material are preferably three-dimensional and along the x, y and z planes.
The material may be cut so that the slits form a parallel, staggered, patterned or random arrangement.
Cuts are not restricted to any particular geometry; they may be straight-edged or curved. Straight-edged cuts include uni-directional arrangements, where all cuts are parallel, and multi-directional arrangements, where all cuts are non-parallel. Curved-cuts include arrangements radiating in an outwardly direction from a central point of the material and describing a circumference of a circle.
Generally speaking, the greater the number of cuts and thus excise of material, the more flexible and extensible will be the lattice formed from the material. However, the geometry of the cutting arrangement will also alter the mechanical properties of the material. Each different cutting geometry will provide a lattice having somewhat different mechanical properties and thus provide lattices of different flexibility and extensibility.
When cutting slits into the material to form the lattice, it is preferable that a minimum amount of material is removed. This avoids the detrimental effect on the structural integrity, and more particularly the mechanical strength of the lattice formed, which would otherwise happen where a larger amount of material was removed as in the case of the prior art where material is removed to form holes.
Preferably, the amount of material removed to form the lattice is therefore, for example, less than about 50% of the initial material volume, more preferably less than about 10% of the initial material volume, and ideally, less than about 1% of the initial material volume. Preferably, the excise of material to form the lattice gives rise to no or substantially no visual removal of material.
When the slits have been formed by cutting the material, the surface area of the resulting lattice can be extended, to about 25%-75% greater than the surface area of the original material. Extension of the lattice opens the slits forming a plurality of apertures/structural voids of a first dimension. The lattice in this extended form is referred to as an open lattice or having an “open lattice conformation”, “second conformation” or “extended conformation”.
The open lattice is established by an extensive force prior to or immediately prior to and during attachment to the site of application, for example, a wound site.
The lattice has a top or non-wound contacting surface and a bottom or wound contacting surface. The open lattice can be made from any suitable extendible material, for example, polyurethane foam.
The extensive force can be applied to the lattice in a unidirectional, bidirectional or isotropical manner and can be achieved by any means known to the skilled artisan, for example by drawing between rollers running at differential speeds. A process of extending the material in a controlled manner is considered particularly advantageous as this allows apertures/structural voids of predetermined dimensions and of particular interest to be formed.
Preferably, the lattice is extended to 25-75% of its maximum geometrical extension limit. The maximum geometrical extension limit is defined as the point at which the rate of change of the open volume or area of the apertures is zero or substantially zero. More preferably, the lattice is extended to maximise the open volume or area of the apertures, which may not necessarily be related to the maximum geometric extension.
Preferably, once the lattice has been extended into its second conformation, it can be retained in this conformation by the use of a retaining means. The retaining means may be adhered to a surface of the open lattice in any conventional manner. The retaining means can be a physical entity, such as a structural element, for example.
In an embodiment of the invention, the structural element can be a mechanically stiff backing layer, for example, the backing layer being stiff enough to maintain the extended open lattice conformation prior to and during application of the lattice to the wound site. The backing layer may comprise any suitable material, but is preferably plastic or paper.
Additionally, the backing layer is easily releasable from the material. The release of the backing layer may be facilitated by a release tab or gripping portion associated with the backing layer.
The backing layer can be applied directly or indirectly to the open lattice, thus retaining and supporting it in the extended, or second or open lattice conformation prior to and during application. The backing layer has a sufficient mechanical stiffness to resist the inherent contractile force of the open lattice when the extensive force is removed, thereby retaining the lattice in the extended or open lattice conformation. Once the open lattice has been applied to the wound site the backing layer is removed. On removal of the backing layer, the contractile force is transferred to the wound site promoting closure of the wound. Removal of the backing layer also causes the surface area of the lattice and the volume of the voids established therein by the extensive force to shrink.
The extensive force applied to the lattice to form the open lattice is translated into a contractile force when the extensive force is removed. In embodiments of the invention more than about 10% of the extensive force is translated to a contractile force upon removal of the retaining means. In preferred embodiments of the invention more than about 50% of the extensive force is translated to a contractile force upon removal of the retaining means.
In this manner, a contractile force can be applied to the site of application. The use of such a lattice at a wound site, either directly or indirectly (for example, as part of a wound dressing) has the advantage of promoting wound closure, as a result of the contractile forces pulling the edges of the wound together.
By controlling the lattice and open lattice geometry (both the cut and the orientation of extension), it is possibly to control the geometry of the contractile force.
Upon removal of the retaining means, the open lattice preferably recovers more than 1% of the difference between its dimensions prior to extension and those same dimensions post-extension. More preferably, the open lattice recovers more than about 5% of the difference, and ideally recovers more than 10% of the difference.
In this embodiment of the invention, the greater the extension of the lattice the greater will be the contractile force on removal of the backing layer.
The invention is also concerned with the application of the open lattice both internally and externally of the body and on normal or injured tissue such that, following application of the open lattice, the extensive force can be released and transmitted to the attached tissue as a compressive force.
For the contraction of linear wounds, for example post-operative surgical incisions, lattices extensible along a single axis are preferred, as these lattices will impart contraction along a single axis, which when the lattice is appropriately position on the wound will be directed perpendicular to the line of the incision. For the contraction of two-dimensional wounds, for example chronic wounds such as pressure ulcers, lattices extensible along multiple axes are preferred.
Preferably, the lattice is extensible in a mechanically isotropic manner, enabling wound contraction to be directed towards the centre of the wound.
Alternative embodiments provide for the backing layer to be fixed to the non-wound contact surface of the open lattice. In this case the backing layer is a transparent material so that visual inspection of the wound is possible through the apertures of the lattice. It will be appreciated that in this embodiment, no contractile force is applied to the wound from the open lattice.
In another embodiment of the invention, the lattice can be of a material which allows it to also function as the retaining means. For example, the lattice can be made from so-called SMART materials (also referred to as shape-memory materials). The shape of SMART materials can be altered in a controlled fashion by external stimuli, such as stress, temperature, moisture, pH, electric or magnetic fields. In embodiments of the invention, the material is a SMART material. The lattice formed from the SMART material is extended into and retained in the second or open lattice conformation by the application of one or more external stimuli. Post-application of the open lattice to a wound site, further controlled exposure of the open lattice to an external stimulus would result in the open lattice fully or partially contracting to its original, “remembered” dimensions or first conformation. In a wound site, the open lattice could also be initiated or encouraged to contract by exposure to the moisture content of a wound exudate.
In another embodiment of the invention, the structural element can be a transparent film, for example a polyurethane film, fixedly or removably applied to the non-wound contact surface of the open lattice or to the non-wound contact surface and wound contact surface of the open lattice. The film is not as structurally rigid or stiff as the backing layer so that it can not hold the open lattice in a sufficiently extended form to provide a contractile force to promote closure of the wound if removed. Instead, the film keeps a more relaxed open conformation so that the slits remain apertures to allow visual inspection of the wound. The film of this embodiment also acts as a bacterial barrier which is particularly important when the lattice is administered to external wounds.
In further embodiments, both the film and backing layer may be used. The backing layer forms the external non-wound contacting surface and may be removable or fixed.
In yet a further embodiment, the lattice can be extended by hand. Gripping portions or tabs maybe provide at a periphery of the material to give the hand purchase, for example, aiding extension of the lattice by hand. The gripping tabs can be located to allow a more effective extension of the lattice and formation of apertures or structural voids from the slits. Once the lattice has been applied to the wound site the gripping portions are released. On release of the gripping portions, the contractile force of the open lattice is transferred to the wound site promoting closure of the wound. Release of the gripping portions also causes the surface area of the open lattice and the volume of the voids established therein, by the extensive force, to shrink. After the lattice has been secured to the wound site, the gripping portions can be removed from the lattice by cutting, for example. This will prevent the free ends of the gripping portions from snagging. Preferably, the lattice also has a polyeurethane film attached to both the wound and non-wound contact surfaces of the lattice. The polyurethane film will extend with the lattice to form an open lattice and will also act as a bacterial barrier.
In embodiments of the invention the lattice is a wound dressing. In alternative embodiments of the invention the lattice can form a part (for example a layer) of a wound dressing.
In an example of the lattice being incorporated into a wound dressing, a moisture permeable top-film can be applied to the non-wound contacting surface of the lattice (for example, by heat lamination), and the removable backing layer applied to the top-film. The top film can be a polyurethane film, for example. Optionally, a perforated layer of polyurethane film can be applied to the wound contact surface of the polyurethane foam lattice. The polyurethane film applied in this way will prevent the polyurethane foam sticking to the wound which may otherwise occur.
Therefore, according to a further aspect of the invention there is provided a wound dressing consisting of or comprising the lattice of the invention.
In an embodiment of this aspect of the invention the lattice material is a polyurethane foam and the retaining means is a backing sheet adhered temporarily to a non wound contacting surface of the lattice (for example, by a suitable adhesive or surface energy). The backing sheet is of a plastic material (for example, a polymeric film) or paper material (for example, reinforced paper or cardboard). The backing sheet is removed from the open lattice once the wound dressing has been applied to the wound by any suitable means known in the art, for example, by adhesive, sutures, staples or topical pressure.
Preferably, the material is sufficiently elastic to allow a return, unaided or unhindered, of the open lattice to the first conformation, wherein the slits are substantially closed, after being stretched, deformed, compressed, or expanded. Materials conventionally utilised in wound dressings, such as foams (for example, polyurethane foam), silicone-based material (for example, a silicone elastomer), hydrofibre, films, non-woven and woven materials, demonstrate such elastic properties and are suitable materials.
Such elasticity results in the material exerting a spring-like contractile force following the removal of the extensive force, for example, by the removal of the retaining means. This contractile force results in the open lattice forming a “third conformation” or “contracted conformation”, in which the apertures/structural voids are contracted to a smaller, second dimension.
In embodiments of the invention the material is a monolith.
According to a further aspect of the invention there is provided a wound dressing comprising a material having;
The material of this aspect of the invention is sufficiently expandable and contractible (partially or fully) from and to an initial conformation, without the requirement for the provision of slits. For example, the material can have elastic properties which closely resemble, for example, LYCRA® (Invista, US).
In an embodiment of this aspect of the invention, the material is provided with at least one slit and preferably with a plurality of slits.
According to a further aspect of the invention there is provided a method of promoting the closure of a wound, the method comprising the steps of;
In embodiments of the invention the open lattice can be applied directly to a wound. In alternative embodiments of the invention the open lattice can form a part (for example a layer) of a wound dressing which is applied to a wound.
The invention is particularly suited for application to topical and internal wounds, for example traumatic injuries, surgical incision wounds and open chronic wounds. Surgical wounds include those that are the result of plastics or maxillofacial operations, mastectomy or caesarean section.
The direction of the contractile force is influenced by the geometry of cut in the material to form the lattice, the geometry of extension of the lattice and the geometry of the attachment points between the lattice or wound dressing and the tissue.
The open lattice or wound dressing can be applied to the wound site using any suitable technique and attachment means known in the art, for example, adhesive, sutures, staples or topical pressure. Topical pressure can be provided by compression bandaging or atmospheric pressure acting upon a cavity of reduced pressure relative to the external atmosphere. Attachment can be achieved at specific locations on the open lattice or wound dressing or may cover the entire surface thereof. For topical applications, attachment is preferably achieved by an area exceeding 50% of the total area of the open lattice or wound dressing in contact with the site of application. More preferably, for topical applications, attachment is achieved by a pressure sensitive adhesive, for example an acrylate-based adhesive. Typically, the adhesive forms a layer on the wound contact surface of the open lattice or wound dressing.
According to a further aspect of the invention there is provided a method of manufacturing a wound dressing comprising the steps of,
Preferably, the method of manufacture includes the step of forming at least one slit and more preferably a plurality of slits in the material to form a lattice. According to yet a further aspect of the invention there is provided a method of manufacturing a wound dressing comprising the steps of,
Preferably, the method of manufacture includes the steps of,
Examples of materials for use as the first material, include foams, such as polyurethane foam and silicone-based elastomers.
An example of a suitable material for use as the retaining means is a polymeric film, such as polyurethane film. Other suitable materials include polyester, polyethylene and polypropylene which can be perforated or extruded net.
In some embodiments, there is provided a wound dressing comprising a body of porous material, the body of porous material comprising a plurality of cuts which provide regions of flexibility within the body.
While the plurality of cuts provide regions of flexibility within the body, they are not capable of rendering portions of the body frangible, such that the portions are relatively easily severable from the body.
Preferably the porous material is a wound packing foam suitable for use in negative pressure wound therapy (NPWT). Particularly suitable foams for NPWT include polyurethane foam, typically reticulated polyurethane foam of very high free internal volume, e.g. 80% or higher, preferably 90% or higher free internal volume. Typical foams used in NPWT have porosities in the range 30-60 ppi (pores per inch) and mean pore diameters in the range 300-800 μm. However, other suitable foams are known in the art and may be equally employed. In general suitable foams have an open porous structure, to allow transmission of the negative pressure to the wound bed, and sufficient mechanical strength to prevent the negative pressure (typically approximately 80-125 mm Hg below ambient atmospheric pressure) from collapsing the structure of the foam.
Suitably the cuts are slits. Herein this section and elsewhere in this specification, the term slit is intended to mean a cut which is generally long and thin, and preferably straight and linear. In practice, slits in foam are typically effectively 2-dimensional as the resilience of the foam means that the slit is essentially closed unless the material is stretched. Suitably the slits are from 10 mm to 70 mm in length, preferably from 20 mm to 50 mm, especially from 25 mm to 40 mm. Slits of around 30 mm have been found to be particularly effective in a typical NPWT, though there is of course scope to vary this.
Providing cuts, e.g. slits, confers macroscopic flexibility, while not substantially affecting the microscopic mechanical properties of the body, i.e. to resist compression under negative pressure. This flexibility allows the body of porous material to drape more easily, i.e. to conform to the shape of the wound to be dressed.
In a preferred embodiment, the body comprises at least one linear series of slits, each slit being separated from an adjacent slit by a gap. By “linear series of slits” it is intended to mean a plurality of generally linear slits, each slit generally aligned along a straight line in a series, with a gap separating each slit from adjacent slits in the series. Generally it is preferred that the gaps are regularly sized.
Preferably the body comprises two or more parallel linear series of slits, each linear series being spaced from the adjacent linear series. Preferably the spacing between the adjacent linear series is regular.
It will be clear to the person skilled in the art that the size of the gap between the slits, and the spacing between adjacent series, must be sufficient such that the material retains structural integrity sufficient for it to be handled, used in therapy and removed thereafter without breaking up. If the gaps and spacing were too small, the body would be too weak to achieve this. On the other hand, there is a desire to maximise the size and density of the slits to maximise drapeability. It is preferred that the minimum size of the gaps and/or spacing should certainly be no less than the average pore diameter. It is more preferred that gaps and/or spacing are at least 5 times the average pore diameter; given that the average pore diameter for NPWT foam is in the range of 300-800 μm, this gives a gap or spacing of 1500 to 4000 μm, i.e. 1.5 to 4 mm. A gap of around 3 mm has been found to be particularly effective in a typical NPWT, though there is of course scope to vary this.
It is preferable that the spacing between adjacent linear series of slits is kept reasonably small to provide the desired amount of flexibility and hence drapeability. Accordingly, it is preferred that the spacing is not more than 50 times the average pore diameter (typically from 15 mm to 40 mm depending on pore density), preferably not more than 30 times than average pore diameter (typically from 9 mm to 24 mm depending on pore density). A spacing of around 3 mm has been found to be particularly effective in a typical NPWT, though there is of course scope to vary this.
It is preferred that, where two or more parallel linear series of slits are provided, adjacent series are linearly offset relative to each other, i.e. it is preferred that the slits and gaps in adjacent series do not line up, but are staggered. To put it another way, adjacent series may be out of phase with each other. In one embodiment adjacent series are offset such that the centre point of a slit in one series is aligned approximately with the gap in an adjacent series—similar to the way layers of bricks are offset in a wall. There is of course scope to vary the amount of offset.
This offset of adjacent series of slits allows for particularly good drapeability. When the body is curved the slits open up to form a lattice type structure which is particularly suited to provide good flexibility, and hence drapeability.
The slits may suitably pass completely through the thickness of the body. Alternatively the slits may pass only partially though the thickness of the body, provided they pass through far enough to provide the desired flexibility to the body. In general it is preferred that the slits pass at least half way through the thickness of the body, preferably at least three quarters of the way through the body, and especially substantially all the way through the body.
The present application is particularly suited to a wound dressing material comprising a body of porous material which is relatively thin, although it could be used to impart flexibility to a body which is thick. In particular, the present invention is particularly suited to a sheets of porous material which have a thickness of from 5 mm to 75 mm, preferably from 10 mm to 50 mm, especially from 15 to 40 mm, most preferably from 20 to 35 mm. In a very thin sheet (less than 5 mm) drapeability of the sheet is not such an issue, and where the thickness is greater than about 75 mm, providing a plurality of cuts becomes less effective as a means of introducing flexibility. Thus the ranges set out above represent sheets of thicknesses which are particularly well suited to the present invention. The other dimensions of the sheet are not particularly significant, although it may be observed that NPWT foam is typically sold in generally cuboid sheets with the dimensions of the edges of largest face being between 100 and 200 mm, e.g. a sheet measuring 100×200×30 mm is fairly typical.
It is generally preferred that the cuts are provided passing through the shortest dimension of the body. In particular it is preferred that the cuts (e.g. slits) are provided passing between the two largest faces of a cuboid body (e.g. sheet), and especially that the cuts are perpendicular to the largest faces.
Where two or more parallel linear series of slits are provided, as set out above, this provides for good flexibility in a single direction of curve. When a body is curved around a surface, the inside of the body is subject to compression and the outside of the body is subjected to tension (inside and outside being defined relative to the curve). In wound dressings according to the present invention the cuts allow the body to stretch when under tension, the cuts allowing deformation of the shape of the body (e.g. into a lattice), and this allows the body to easily adapt to the desired curve. Where the cuts comprise slits in a single orientation, the body will be well adapted to curving in a direction which causes tension perpendicular to the slits, but will be less well adapted to curving in another direction, i.e. where the tension produced is parallel to the slits. Therefore, the body is well suited to drape around a body with a single curvature (e.g. generally cylindrical), but not so well suited to draping around a more complex curved object such as a generally spherical shape.
In a further embodiment of the present invention, the body comprises a second set of slits passing at least partially through the body in a different orientation (preferably perpendicular) to the slits in the at least one linear series of slits described above (the “first set of slits”). It is preferred that the second set of slits also pass between, and are perpendicular to, the largest faces of the body. Additional slits provided in this manner allow the body to curve more easily in a second direction thus making it more suited to adapting to a complex curved surface, i.e. curved in two planes.
In a preferred embodiment of the invention at least some of the slits in both orientations intersect. Suitably the intersection of the slits effectively provides a two-dimensional (2-D) slit. Preferably the 2-D slit has an H shape, with a two parallel slits in one orientation being intersected at their mid-points by a third slit in a perpendicular orientation. Such an H-shaped 2-D slit is well suited to the provision of a relatively dense array of 2-D slits in the body. For example, rows of H-shaped slits, each adjacent slit within the row alternating in orientation by 90 degrees, can be packed closely together, while obeying the minimum spacing requirements set out above.
In a preferred embodiment of the invention, the body comprises a first set of parallel linear series of H-shaped slits in a first orientation and a second set of parallel linear series of H-shaped slits in a second orientation. Preferably the second orientation is perpendicular to the first orientation. Preferably adjacent series within a set are offset relative to one another. Such an arrangement allows very close packing of the H-shaped slits, whilst maintaining a suitable spacing between neighbouring slits to retain the overall structural integrity of the body. To allow close packing of the slits it is preferred that the length of the two parallel slits (the “sides”) of the H-shaped slit are shorter than the perpendicular slit (the “cross-piece”) of the H-shaped slit. For example, the “cross-piece” may be from 10 mm to 70 mm in length, preferably from 20 mm to 50 mm, especially from 25 mm to 40 mm, most preferably 30 mm and the “sides” are preferably around 6 mm shorter than the “cross-piece”, especially around half the length of the “cross-piece”. Where the “sides” of the H are shorter than the “cross-piece”, it allows the “sides” of H-shaped slits in one orientation to nest within the area bounded by “sides” and “cross-piece” of the H-shaped slit in the other orientation. This allows for very close packing of the H-shaped slits.
It should be noted that while a body having an array of H-shaped 2-D slits is a preferred embodiment of the present invention, it is possible to achieve a suitable 2-D array using other shapes, such as cruciform slits, or the like.
It should be noted that the cuts, e.g. slits, of the present invention can be provided by cutting a preformed body of foam, or the cuts could be provided during the process in which the body is manufactured (e.g. moulding). It is preferred that the cuts are provided by die cutting a preformed body.
In a further aspect, the present invention provides a method of manufacturing a wound dressing, the method comprising the steps of;
It is preferred that the cuts are provided by die cutting using an array of suitably sized and shaped blades to provide the desired cuts.
Details of preferred cuts, e.g. slits, are set out above, and it will be obvious to the person skilled in the art how to provide a suitable blade to achieve the desired cut.
The cuts may be provided all the way through the body, or they may only pass partially through the body.
The cuts may be formed in a batch, or they may be formed in a flow process.
In a further aspect the present invention provides a method of dressing a wound comprising administering a wound dressing as set out above to the wound.
Preferably the method provides the step of applying a negative pressure to the wound through the wound dressing material, i.e. the method is NPWT. In general this can be achieved by providing a substantially fluid impermeable sheet over the wound and wound dressing, thus defining a sealed volume, and applying a negative pressure inside said sealed volume. The seal need not be completely hermetic, but should be sufficient to allow a suitable negative pressure to be sustained. The source of negative pressure, e.g. a pipe form a vacuum pump, can be provided at a position such that it draws fluids from the wound bed through the wound dressing material.
Suitably the negative pressure is in the range of from 80 to 125 mm Hg below ambient atmospheric pressure.
In a further aspect the present invention provides the use of a wound dressing material as set out above in wound treatment, especially NPWT.
Other features and advantages of the present invention will be apparent from the following detailed description of the invention, taken in conjunction with the accompanying drawings of which:
Like reference numbers refer to corresponding parts throughout the drawings, description and examples.
To create the wound dressing of example 1, a perforated sheet of polyurethane film was applied to the wound contact surface of a sheet of 4 mm depth polyurethane foam (Allevyn, Smith & Nephew Medical Limited).
The wound contact surface is that surface which is placed adjacent to or in direct contact with the wound. The non-wound contact surface is that surface which is remote from or opposite the wound contact surface.
A cutter of specification shown in
Following cutting, an extensive force was applied to the lattice in a direction perpendicular to the longitudinal axis of the cuts or slits to produce an open lattice as shown in
To create the wound dressing of example 2, a perforated sheet of adhesive polyurethane film was applied to the wound contact surface of a sheet of 4 mm depth polyurethane foam (Allevyn, Smith & Nephew Medical Limited). The adhesive surface of the film was covered by a siliconised release paper. A cutter of specification shown in
The wound contact surface is that surface which is placed adjacent to or in direct contact with the wound. The non-wound contact surface is that surface which is remote from or opposite the wound contact surface.
Following cutting, the siliconised release paper was removed and an extensive force was applied to the lattice in a direction perpendicular to the longitudinal axis of the cuts or slits to produce the open lattice pattern as shown in
To demonstrate the effectiveness of the wound dressing of example 2, the siliconised release paper was removed from the perforated adhesive film and placed, adhesive side down, upon intact skin. The polymeric film release sheet was then removed. A uni-directional contractile force was generated on the skin, upon removal of the polymeric film release sheet, and in a direction perpendicular to the axis of the cuts.
To create the wound dressing of example 4, a perforated sheet of polyurethane film was applied to the wound contact surface of a sheet of 4 mm depth polyurethane foam (Allevyn, Smith & Nephew Medical Limited). A cutter of specification shown in
The wound contact surface is that surface which is placed adjacent to or in direct contact with the wound. The non-wound contact surface is that surface which is remote from or opposite the wound contact surface.
Following cutting, the lattice was extended along two axes, x and y, as shown in
To create the wound dressing of example 5, a perforated sheet of adhesive polyurethane film was applied to the wound contact surface of a sheet of 4 mm depth polyurethane foam (Allevyn, Smith & Nephew Medical Limited). The adhesive surface of the film was covered by a siliconised release paper. A cutter of specification shown in
The wound contact surface is that surface which is placed adjacent to or in direct contact with the wound. The non-wound contact surface is that surface which is remote from or opposite the wound contact surface.
Following cutting, the siliconised release paper was removed and the lattice was extended along two axes, x and y, as shown in
The lattice of the wound dressing of example 5, having the polymeric film release sheet removed, it shown in
To demonstrate the effectiveness of the wound dressing of example 5, the siliconised release paper was removed from the perforated adhesive film and placed, adhesive side down, upon intact skin. The polymeric film release sheet was then removed. Upon removal of the polymeric film release sheet, a contractile force was generated on the skin acting towards the centre of the dressing.
A similar process to that described for the wound dressing of example 5 is employed to create the wound dressing of example 7. However, in this case, a cutter of specification shown in
The lattice of the wound dressing of example 7, having the polymeric film release sheet removed, it shown in
An array of blades (10) mounted on a board is shown in
A body of NPWT foam (20) measuring 200×125×30 mm is cut using the array (10). It is cut by driving the array of blades (10) through the body (20) in a die cutting operation. This can be achieved using a press, typically a hydraulic press (not shown), also known as a clicker press. The blades are driven perpendicularly into and through the largest face of the body (20), and perpendicular thereto, to form a plurality of slits therein. The slits (21) formed are arranged in a plurality of parallel linear series (26,28) of slits, each comprising slits (21) 30 mm long separated by gaps (22), where material is left un-cut, which are 3 mm long. Each series is separated by a spacing (24) 3 mm in width. When the body (20) is curved, as shown in
In the embodiment shown in
It should be noted that the present description has focused on bodies formed by a batch die cutting process. There are of course numerous ways of forming cuts in a body of porous material (e.g. laser cutting, high pressure liquid cutting), or the cuts could formed when the body itself is formed (e.g. during a moulding process). Furthermore, these methods could be applied in a flow process rather than a batch; this might be more efficient for large production runs. All such variations are within the scope of the present invention.
Furthermore, it should be noted that, while the exemplified embodiments form particularly preferred embodiments with excellent drapeability, it is quite possible that other arrangements of cuts will provide satisfactory results.
Number | Date | Country | Kind |
---|---|---|---|
0903032.1 | Feb 2009 | GB | national |
This application is a continuation in part of U.S. patent application Ser. No. 12/443,169, filed Nov. 17, 2009, entitled LATTICE DRESSING, which is a National Phase Application of PCT Patent Application No. PCT/US2007/079529 filed Sep. 26, 2007, entitled LATTICE DRESSING, which claims priority to U.S. Provisional Application No. 60/826,922, filed Sep. 26, 2006, entitled LATTICE DRESSING. This application is also a continuation-in-part of U.S. patent application Ser. No. 13/202,974, filed Oct. 5, 2011, entitled DRAPEABLE WOUND DRESSING, which is a National Phase Application of PCT Patent Application PCT/GB2010/000293, filed Feb. 19, 2010, entitled DRAPEABLE WOUND DRESSING, which claims priority to Great Britain Application No. 0903032.1, filed Feb. 24, 2009, entitled DRAPEABLE WOUND DRESSING. The contents of the aforementioned applications are hereby incorporated by reference in their entireties as if fully set forth herein. The benefit of priority to the foregoing applications is claimed under the appropriate legal basis, including, without limitation, under 35 U.S.C. § 119(e).
Number | Name | Date | Kind |
---|---|---|---|
1975504 | Formhals | Oct 1934 | A |
2877765 | Bunyan | Mar 1959 | A |
2889039 | Schladermundt et al. | Jun 1959 | A |
3073304 | Schaar | Jan 1963 | A |
3972328 | Chen | Aug 1976 | A |
4029598 | Neisius et al. | Jun 1977 | A |
4294240 | Thill | Oct 1981 | A |
4418691 | Yannas et al. | Dec 1983 | A |
4541426 | Webster | Sep 1985 | A |
4664662 | Webster | May 1987 | A |
4728499 | Fehder | Mar 1988 | A |
4813942 | Alvarez | Mar 1989 | A |
4841961 | Burlage et al. | Jun 1989 | A |
4841962 | Berg et al. | Jun 1989 | A |
4929477 | Will | May 1990 | A |
5010883 | Rawlings et al. | Apr 1991 | A |
5056510 | Gilman | Oct 1991 | A |
5061258 | Martz | Oct 1991 | A |
5145906 | Chambers et al. | Sep 1992 | A |
5167613 | Karami et al. | Dec 1992 | A |
5181905 | Flam | Jan 1993 | A |
5238732 | Krishnan | Aug 1993 | A |
5267952 | Gardner | Dec 1993 | A |
5397316 | LaVon et al. | Mar 1995 | A |
5415715 | Delage et al. | May 1995 | A |
5489304 | Orgill et al. | Feb 1996 | A |
5536555 | Zelazoski | Jul 1996 | A |
5549584 | Gross | Aug 1996 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5645081 | Argenta et al. | Jul 1997 | A |
5707499 | Joshi et al. | Jan 1998 | A |
5713881 | Rezai et al. | Feb 1998 | A |
5716411 | Orgill et al. | Feb 1998 | A |
5720714 | Penrose | Feb 1998 | A |
5759570 | Arnold | Jun 1998 | A |
5795439 | Euripides | Aug 1998 | A |
5804021 | Abuto et al. | Sep 1998 | A |
5852126 | Barnard et al. | Dec 1998 | A |
5868724 | Dierckes, Jr. | Feb 1999 | A |
5981822 | Addison | Nov 1999 | A |
6071267 | Zamierowski | Jun 2000 | A |
6167613 | Karami | Jan 2001 | B1 |
6203654 | McFall et al. | Mar 2001 | B1 |
6207875 | Lindqvist et al. | Mar 2001 | B1 |
6297422 | Hansen et al. | Oct 2001 | B1 |
6333093 | Burrell et al. | Dec 2001 | B1 |
6345623 | Heaton et al. | Feb 2002 | B1 |
6566575 | Stickels et al. | May 2003 | B1 |
6626891 | Ohmstede | Sep 2003 | B2 |
6685681 | Lockwood et al. | Feb 2004 | B2 |
6713659 | Bodenschatz et al. | Mar 2004 | B2 |
6752794 | Lockwood et al. | Jun 2004 | B2 |
6770794 | Fleischmann | Aug 2004 | B2 |
6794554 | Sessions et al. | Sep 2004 | B2 |
6936037 | Bubb et al. | Aug 2005 | B2 |
6942628 | Watson | Sep 2005 | B1 |
6951553 | Bubb et al. | Oct 2005 | B2 |
6979324 | Bybordi et al. | Dec 2005 | B2 |
7004915 | Boynton et al. | Feb 2006 | B2 |
7070584 | Johnson et al. | Jul 2006 | B2 |
7108681 | Gartstein et al. | Sep 2006 | B2 |
7108683 | Zamierowski | Sep 2006 | B2 |
7122712 | Lutri et al. | Oct 2006 | B2 |
7216651 | Argenta et al. | May 2007 | B2 |
7351250 | Zamierowski | Apr 2008 | B2 |
7361184 | Joshi | Apr 2008 | B2 |
7381859 | Hunt et al. | Jun 2008 | B2 |
7438705 | Karpowicz et al. | Oct 2008 | B2 |
7468471 | Sigurjonsson et al. | Dec 2008 | B2 |
7494482 | Orgill et al. | Feb 2009 | B2 |
7569742 | Haggstrom et al. | Aug 2009 | B2 |
7576256 | Björnberg et al. | Aug 2009 | B2 |
7605298 | Bechert et al. | Oct 2009 | B2 |
7615036 | Joshi et al. | Nov 2009 | B2 |
7622629 | Aail | Nov 2009 | B2 |
7625362 | Boehringer et al. | Dec 2009 | B2 |
7676400 | Dillon | Mar 2010 | B1 |
7676784 | Allen et al. | Mar 2010 | B2 |
7699823 | Haggstrom et al. | Apr 2010 | B2 |
7700819 | Ambrosio et al. | Apr 2010 | B2 |
7708724 | Weston | May 2010 | B2 |
7718249 | Russell et al. | May 2010 | B2 |
7722582 | Lina et al. | May 2010 | B2 |
7749531 | Booher | Jul 2010 | B2 |
7754937 | Boehringer et al. | Jul 2010 | B2 |
7759537 | Bishop et al. | Jul 2010 | B2 |
7759539 | Shaw et al. | Jul 2010 | B2 |
7775998 | Riesinger | Aug 2010 | B2 |
7779625 | Joshi et al. | Aug 2010 | B2 |
7811269 | Boynton et al. | Oct 2010 | B2 |
7815616 | Boehringer et al. | Oct 2010 | B2 |
7820453 | Heylen et al. | Oct 2010 | B2 |
7838717 | Haggstrom et al. | Nov 2010 | B2 |
7846141 | Weston | Dec 2010 | B2 |
7857806 | Karpowicz et al. | Dec 2010 | B2 |
7896856 | Petrosenko et al. | Mar 2011 | B2 |
7909805 | Weston | Mar 2011 | B2 |
7910791 | Coffey | Mar 2011 | B2 |
7922703 | Riesinger | Apr 2011 | B2 |
7942866 | Radl et al. | May 2011 | B2 |
7951124 | Boehringer et al. | May 2011 | B2 |
7959624 | Riesinger | Jun 2011 | B2 |
7964766 | Blott et al. | Jun 2011 | B2 |
7976519 | Bubb et al. | Jul 2011 | B2 |
7981098 | Boehringer et al. | Jul 2011 | B2 |
7982087 | Greener et al. | Jul 2011 | B2 |
8030534 | Radl et al. | Oct 2011 | B2 |
8034037 | Adams | Oct 2011 | B2 |
8062272 | Weston | Nov 2011 | B2 |
8062331 | Zamierowski | Nov 2011 | B2 |
8070773 | Zamierowski | Dec 2011 | B2 |
8080702 | Blott et al. | Dec 2011 | B2 |
8114126 | Heaton et al. | Feb 2012 | B2 |
8118794 | Weston et al. | Feb 2012 | B2 |
8123781 | Zamierowski | Feb 2012 | B2 |
8142419 | Heaton et al. | Mar 2012 | B2 |
8172816 | Kazala, Jr. et al. | May 2012 | B2 |
8187237 | Seegert | May 2012 | B2 |
8188331 | Barta et al. | May 2012 | B2 |
8197467 | Heaton et al. | Jun 2012 | B2 |
8207392 | Haggstrom et al. | Jun 2012 | B2 |
8235972 | Adahan | Aug 2012 | B2 |
8246607 | Karpowicz et al. | Aug 2012 | B2 |
8273105 | Cohen et al. | Sep 2012 | B2 |
8282611 | Weston | Oct 2012 | B2 |
8303552 | Weston | Nov 2012 | B2 |
8338402 | Fry et al. | Dec 2012 | B2 |
8353931 | Stopek et al. | Jan 2013 | B2 |
8376972 | Fleischmann | Feb 2013 | B2 |
8399730 | Kazala, Jr. et al. | Mar 2013 | B2 |
8409159 | Hu et al. | Apr 2013 | B2 |
8444392 | Turner et al. | May 2013 | B2 |
8444612 | Patel et al. | May 2013 | B2 |
8447375 | Shuler | May 2013 | B2 |
8460255 | Joshi et al. | Jun 2013 | B2 |
8460257 | Locke et al. | Jun 2013 | B2 |
8486032 | Seegert et al. | Jul 2013 | B2 |
8500704 | Boehringer et al. | Aug 2013 | B2 |
8500776 | Ebner | Aug 2013 | B2 |
8523832 | Seegert | Sep 2013 | B2 |
8535296 | Blott et al. | Sep 2013 | B2 |
8540687 | Henley et al. | Sep 2013 | B2 |
8545464 | Weston | Oct 2013 | B2 |
8545466 | Andresen et al. | Oct 2013 | B2 |
8608776 | Coward et al. | Dec 2013 | B2 |
8622981 | Hartwell et al. | Jan 2014 | B2 |
8628505 | Weston | Jan 2014 | B2 |
8632523 | Eriksson et al. | Jan 2014 | B2 |
8641691 | Fink | Feb 2014 | B2 |
8679080 | Kazala, Jr. et al. | Mar 2014 | B2 |
8679153 | Dennis | Mar 2014 | B2 |
8680360 | Greener et al. | Mar 2014 | B2 |
8708984 | Robinson et al. | Apr 2014 | B2 |
8791316 | Greener | Jul 2014 | B2 |
8795243 | Weston | Aug 2014 | B2 |
8821535 | Greener | Sep 2014 | B2 |
8829263 | Haggstrom et al. | Sep 2014 | B2 |
8834451 | Blott et al. | Sep 2014 | B2 |
8945030 | Weston | Feb 2015 | B2 |
8956336 | Haggstrom et al. | Feb 2015 | B2 |
9012714 | Fleischmann | Apr 2015 | B2 |
9061095 | Adie et al. | Jun 2015 | B2 |
9168330 | Joshi et al. | Oct 2015 | B2 |
9220822 | Hartwell et al. | Dec 2015 | B2 |
9226737 | Dunn | Jan 2016 | B2 |
9302033 | Riesinger | Apr 2016 | B2 |
9381283 | Adams et al. | Jul 2016 | B2 |
9446178 | Blott et al. | Sep 2016 | B2 |
9452248 | Blott et al. | Sep 2016 | B2 |
9629986 | Patel et al. | Apr 2017 | B2 |
9669138 | Joshi et al. | Jun 2017 | B2 |
9770368 | Robinson et al. | Sep 2017 | B2 |
9795725 | Joshi et al. | Oct 2017 | B2 |
9808561 | Adie et al. | Nov 2017 | B2 |
9820888 | Greener et al. | Nov 2017 | B2 |
20020052570 | Naimer | May 2002 | A1 |
20020193721 | Vandruff | Dec 2002 | A1 |
20030050590 | Kirsch | Mar 2003 | A1 |
20030125646 | Whitlock | Jul 2003 | A1 |
20030203011 | Abuelyaman et al. | Oct 2003 | A1 |
20040019337 | Moberg-Alehammar et al. | Jan 2004 | A1 |
20040057855 | Gerlach et al. | Mar 2004 | A1 |
20050182445 | Zamierowski | Aug 2005 | A1 |
20050215932 | Sigurjonsson et al. | Sep 2005 | A1 |
20060009744 | Edrman et al. | Jan 2006 | A1 |
20060161123 | Kudo et al. | Jul 2006 | A1 |
20070010775 | Lutri | Jan 2007 | A1 |
20070032763 | Vogel | Feb 2007 | A1 |
20070040454 | Freudenberger et al. | Feb 2007 | A1 |
20070055209 | Patel et al. | Mar 2007 | A1 |
20070185463 | Mulligan | Aug 2007 | A1 |
20070225663 | Watt et al. | Sep 2007 | A1 |
20070239232 | Kurtz | Oct 2007 | A1 |
20070282309 | Bengtson et al. | Dec 2007 | A1 |
20080031748 | Ihle et al. | Feb 2008 | A1 |
20080095979 | Hatanaka et al. | Apr 2008 | A1 |
20080132821 | Propp et al. | Jun 2008 | A1 |
20080300555 | Olson et al. | Dec 2008 | A1 |
20080306456 | Riesinger | Dec 2008 | A1 |
20090093550 | Rolfes et al. | Apr 2009 | A1 |
20090105670 | Bentley et al. | Apr 2009 | A1 |
20090105671 | Daggar et al. | Apr 2009 | A1 |
20090137973 | Karpowicz et al. | May 2009 | A1 |
20090227969 | Jaeb et al. | Sep 2009 | A1 |
20100010462 | Kurata | Jan 2010 | A1 |
20100022990 | Karpowicz et al. | Jan 2010 | A1 |
20100106184 | Coward et al. | Apr 2010 | A1 |
20100160874 | Robinson et al. | Jun 2010 | A1 |
20100179515 | Swain et al. | Jul 2010 | A1 |
20100196106 | Allen | Aug 2010 | A1 |
20100249733 | Blott et al. | Sep 2010 | A9 |
20110021964 | Larsen | Jan 2011 | A1 |
20110054283 | Shuler | Mar 2011 | A1 |
20110066096 | Svedman | Mar 2011 | A1 |
20110077605 | Karpowicz et al. | Mar 2011 | A1 |
20110112492 | Bharti et al. | May 2011 | A1 |
20110118683 | Weston | May 2011 | A1 |
20110224631 | Simmons | Sep 2011 | A1 |
20110282310 | Boehringer et al. | Nov 2011 | A1 |
20120041402 | Greener | Feb 2012 | A1 |
20120059412 | Fleischmann | Mar 2012 | A1 |
20120143113 | Robinson et al. | Jun 2012 | A1 |
20120144989 | De Plessis et al. | Jun 2012 | A1 |
20120150133 | Heaton et al. | Jun 2012 | A1 |
20120172926 | Hotter | Jul 2012 | A1 |
20120191054 | Kazala, Jr. et al. | Jul 2012 | A1 |
20120209226 | Simmons et al. | Aug 2012 | A1 |
20130131564 | Locke et al. | May 2013 | A1 |
20130138054 | Fleischmann | May 2013 | A1 |
20130197457 | Kazala et al. | Aug 2013 | A1 |
20130253401 | Locke et al. | Sep 2013 | A1 |
20130274688 | Weston | Oct 2013 | A1 |
20130310781 | Phillips et al. | Nov 2013 | A1 |
20140068914 | Coward et al. | Mar 2014 | A1 |
20140180225 | Dunn | Jun 2014 | A1 |
20150065965 | Haggstrom et al. | Mar 2015 | A1 |
20150112311 | Hammond et al. | Apr 2015 | A1 |
20150148760 | Dodd et al. | May 2015 | A1 |
20150150729 | Dagger et al. | Jun 2015 | A1 |
20150159066 | Hartwell et al. | Jun 2015 | A1 |
20150196431 | Dunn | Jul 2015 | A1 |
20150209492 | Blott et al. | Jul 2015 | A1 |
20170290709 | Adie et al. | Oct 2017 | A1 |
Number | Date | Country |
---|---|---|
34 43 101 | May 1986 | DE |
20 2004 017 052 | Jul 2005 | DE |
10 2005 007016 | Aug 2006 | DE |
0 340 018 | Nov 1989 | EP |
1 320 342 | Jun 2003 | EP |
1 614 789 | Jan 2006 | EP |
1 476 217 | Mar 2008 | EP |
1 955 887 | Aug 2008 | EP |
2 279 016 | Feb 2011 | EP |
2 366 721 | Sep 2011 | EP |
2 462 908 | Jun 2012 | EP |
2 341 955 | Dec 2012 | EP |
2 563 421 | Mar 2013 | EP |
2 567 717 | Mar 2013 | EP |
2 594 299 | May 2013 | EP |
2 601 984 | Jun 2013 | EP |
2 623 137 | Aug 2013 | EP |
2 367 517 | Sep 2013 | EP |
2 544 642 | Jan 2015 | EP |
2 931 197 | Oct 2015 | EP |
3 085 344 | Oct 2016 | EP |
3 139 878 | Mar 2017 | EP |
1 163 907 | Oct 1958 | FR |
821959 | Oct 1956 | GB |
1224009 | Mar 1971 | GB |
1255395 | Dec 1971 | GB |
2195255 | Apr 1988 | GB |
H02-139624 | Nov 1990 | JP |
H02-139625 | Nov 1990 | JP |
H06-339495 | Dec 1994 | JP |
H11-056900 | Mar 1999 | JP |
2004-000465 | Jan 2004 | JP |
WO 198300742 | Mar 1983 | WO |
WO 199010424 | Sep 1990 | WO |
WO 199210983 | Jul 1992 | WO |
WO 199514451 | Jun 1995 | WO |
WO 199601731 | Jan 1996 | WO |
WO 199605873 | Feb 1996 | WO |
WO 199711658 | Apr 1997 | WO |
WO 2002092783 | Nov 2002 | WO |
WO 2003072748 | Sep 2003 | WO |
WO 2004077387 | Sep 2004 | WO |
WO 2005025447 | Mar 2005 | WO |
WO 2005123170 | Dec 2005 | WO |
WO 2006052839 | May 2006 | WO |
WO 2006087021 | Aug 2006 | WO |
WO 2006099137 | Sep 2006 | WO |
WO 2008039223 | Apr 2008 | WO |
WO 2008039839 | Apr 2008 | WO |
WO 2008064502 | Jun 2008 | WO |
WO 2008104609 | Sep 2008 | WO |
WO 2008141228 | Nov 2008 | WO |
WO 2009021523 | Feb 2009 | WO |
WO 2009112848 | Sep 2009 | WO |
WO 2009158131 | Dec 2009 | WO |
WO 2010097570 | Sep 2010 | WO |
WO 2010147535 | Dec 2010 | WO |
WO 2011137230 | Nov 2011 | WO |
WO 2012021553 | Feb 2012 | WO |
WO 2012082716 | Jun 2012 | WO |
WO 2012082876 | Jun 2012 | WO |
WO 2012106590 | Aug 2012 | WO |
WO 2012112204 | Aug 2012 | WO |
WO 2012136707 | Oct 2012 | WO |
WO 2013012381 | Jan 2013 | WO |
WO 2013074829 | May 2013 | WO |
WO 2013136181 | Sep 2013 | WO |
WO 2013175309 | Nov 2013 | WO |
WO 2013175310 | Nov 2013 | WO |
WO 2014013348 | Jan 2014 | WO |
WO 2014014842 | Jan 2014 | WO |
WO 2014014871 | Jan 2014 | WO |
WO 2014014922 | Jan 2014 | WO |
WO 2014165275 | Oct 2014 | WO |
WO 2015172108 | Nov 2015 | WO |
Entry |
---|
“Technology Watch”, May 1989, in 1 page. |
U.S. Appl. No. 15/804,780, filed Nov. 6, 2017, Greener et al. |
U.S. Appl. No. 15/850,996, filed Dec. 21, 2017, Hartwell. |
Alexander, J. Wesley, et al., Clinical Evaluation of Epigard, A New Synthetic Substitute for Homograft and Heterograft Skin, The Journal of Trauma, vol. 13, No. 4, 1973, pp. 374-383. |
Application for Modification to HCPCS Level II Code Set in the 2005-2006 Coding Cycle. Www.cms.hhs.gov/medicare/hcpcs/. |
Blumberg, et al., The Effect of Specific Compression on Soft-Tissue Response to Formalinized PVA (Ivalon) Sponge: A Critical Evaluation, Annals Surg., Mar. 1960, 151(3), 409-418. |
Boland E.D. et al. Utilizing acid pre-treatment and electrospinning to improve biocompatibility poly(glycolic acid) for tissue engineering. J. Biomed. Mater. Res. Part B: Appl Biomater 71B 144-152, 2004. |
Boland et al., “Tailoring Tissue Engineering Scaffolds Using Electrostatic Processing Techniques: A Study of Poly(Glycolic Acid) Electrospinning” Journal of Macromolecular Science A. Pure and Applied Chemistry, A38(12), 1231-1243 (2001). |
Hersle, K. et al., “Uses of Dextranomer Absorbent Pads After Cryosurgery of Cutaneous Malignancies”, The Journal of Dermatologic Surgey and Oncology, vol. 8, Jan. 1982, in 4 pages. |
Hougaard, et al.: “The open abdomen: temporary closure with a modified negative pressure therapy technique,” International Wound Journal, 2014 ISSN 1742-4801, pp. 13-16. |
International Preliminary Report on Patentability, re PCT Application No. PCT/US2007/079529, dated Jan. 5, 2010. |
International Search Report, re PCT Application No. PCT/US2007/079529, dated Mar. 19, 2008, as listed in the revised version of WO 2008/039839 A3, in 6 pages. |
International Search Report, re PCT Application No. PCT/GB2010/000293, dated May 27, 2010. |
International Preliminary Report on Patentability, re PCT Application PCT/GB2010/000293, dated Aug. 30, 2011. |
Kendall ULTEC Hydrocolloid Dressing (4″x4″), product ordering page, web page downloaded Jul. 13, 2014, in 1 page. |
Ma, Peter X. Scaffolds for tissue fabrication. Materials Today, Review, May 2004. |
Advantec MFS, Inc., “Membrane Filters” (catalog), accessed Jan. 29, 2016 (publication date unknown, but believed to be copyright 2001-2011), in 17 pages. URL: http://www.advantecmfs.com/catalog/filt/membrane.pdf#page=11. |
Middleton, J., A. Tipton (Mar. 1998). “Synthetic biodegradable polymers as medical devices” (HTML). Medical Plastics and Biomaterials Magazine. |
Protz, Kerstin: “Moderne Wundauflagen unterstutzen Heilungsprozess”, Wundversorgung: Indikation and Anwendung, Geriatrie Journal, Apr. 2005, pp. 3333-3339, with translation, in 17 pages. |
Smith & Nephew, “PICO Single Use Negative Pressure Wound Therapy System”, spiral booklet, Mar. 2011, in 7 pages. |
Stewart, J., “World Wide Wounds—Next Generation of Products for Wound Management”, 2002, in 13 pages. |
Number | Date | Country | |
---|---|---|---|
20180147091 A1 | May 2018 | US |
Number | Date | Country | |
---|---|---|---|
60826922 | Sep 2006 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15804780 | Nov 2017 | US |
Child | 15879382 | US | |
Parent | 14035487 | Sep 2013 | US |
Child | 15804780 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12443169 | US | |
Child | 14035487 | US | |
Parent | 13202974 | US | |
Child | 14035487 | US |